Patients with type 2 diabetes may face an increased fracture risk when treated with thiazolidinedione (TZD) drugs, data from a large observational study suggest.Use of rosiglitazone (Avandia) or pioglitazone (Actos) was 70% more common among postmenopausal women with diabetes and a history of fractures, compared with a matched control group without fractures. Among diabetic men with a history of fractures, concurrent use of a TZD and a loop diuretic was more than three times as common as in similar men with no history of fractures.
Fracture risk was associated with TZD dose, but the risk was similar for rosiglitazone and pioglitazone, suggesting a class effect, William Herman, MD, of the University of Michigan in Ann Arbor, and co-authors wrote in an article published online in the Journal of Clinical Endocrinology and Metabolism.
via medpagetoday.com
No comments:
Post a Comment